/PRNewswire/ EXoPERT Corporation, a leading developer leveraging Raman Spectroscopy and Artificial Intelligence (AI) for Multi Cancer Early Detection, today.
The FDA sent an email holding the planned Phase I trial for LB1901 after the first and only patient dosed was found to have low CD4+ T-cell counts in the peripheral blood.
The FDA sent an email holding the planned Phase I trial for LB1901 after the first and only patient dosed was found to have low CD4+ T-cell counts in the peripheral blood.